Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R. and Mani, S. (2003) The Bcl2-Family of Protein Ligands as Cancer Drugs: The Next Generation of Therapeutics. Current Medicinal Chemistry-Anti-Cancer Agents, 3, 217-223.
http://dx.doi.org/10.2174/1568011033482459

has been cited by the following article:

• TITLE: Design and Molecular Docking Study of Antimycin A3 Analogues as Inhibitors of Anti-Apoptotic Bcl-2 of Breast Cancer

  AUTHORS: Ade Arsianti,   Fadilah,   Kusmardi, Hiroki Tanimoto, Tsumoru Morimoto, Kiyomi Kakiuchi

  KEYWORDS: Design, Docking, Antimycin A3, Analogue, Bcl-2, Breast Cancer

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.4 No.3, September 23, 2014

  ABSTRACT: In this paper, we report the design and moleculardocking study of analogues of antimycin A3 as inhibitors of anti-apoptotic Bcl-2 of breast cancer. Twenty designed compounds and the original antimycin A3 were docked based on their interaction with breast tumor receptor binding target Bcl-2. The docking resulted in the five top-ranked compounds, namely, compounds 11, 14, 15, 16, and 20, which have a lower G binding energy, better affinity and stronger hydrogen bonding interactions to the active site of Bcl-2 than antimycin A3. Among those five top-ranked compounds, analogue compounds 11 and 14, which have an 18-membered tetralactone core and 18-membered tetraol core, respectively, exhibited the strongest hydrogen bond interaction, formed high stability conformation, and demonstrated the greatest inhibitory activity on the catalytic site of Bcl-2.